Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 11/2009

01-11-2009 | Research Articles

The role of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) in the treatment of peritoneal carcinomatosis in recurrent ovarian cancer

Authors: Francisco C. Muñoz-Casares, Sebastián Rufián, María J. Rubio, Carlos J. Díaz, Rafael Díaz, Ángela Casado, Álvaro Arjona, María C. Muñoz-Villanueva, Jordi Muntané

Published in: Clinical and Translational Oncology | Issue 11/2009

Login to get access
Metadata
Title
The role of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) in the treatment of peritoneal carcinomatosis in recurrent ovarian cancer
Authors
Francisco C. Muñoz-Casares
Sebastián Rufián
María J. Rubio
Carlos J. Díaz
Rafael Díaz
Ángela Casado
Álvaro Arjona
María C. Muñoz-Villanueva
Jordi Muntané
Publication date
01-11-2009
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 11/2009
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-009-0438-3

Other articles of this Issue 11/2009

Clinical and Translational Oncology 11/2009 Go to the issue

Educational Series

Animal models of breast cancer for the study of pathogenesis and therapeutic insights

Educational Series

Telomerase deficiency and cancer susceptibility syndromes

Educational Series

Spanish Society of Medical Oncology consensus on the use of erythropoietic stimulating agents in anaemic cancer patients

Research Articles

High-dose-rate (HDR) plesiotherapy with custom-made moulds for the treatment of non-melanoma skin cancer

Case Reports

Sensory-motor axonal peripheral neuropathy in an advanced breast cancer patient treated with ixabepilone

Reviews

Biomarkers and anti-EGFR therapies for KRAS wild-type metastatic colorectal cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits